Celera and Medco Partner on Statin Drug PGx | GenomeWeb

NEW YORK (GenomeWeb News) – Celera and Medco Health Solutions will collaborate to study whether patients who take a test for a specific gene variant are more likely to adhere to their treatment regimens for lipid-lowering statins.

Celera said today that it will work with Medco to conduct a prospective, randomized, multi-center study to find out if testing for the KIF6 variant can be a predictor for patient adherence.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.